PF-573228

PF-573228 is an ATP-competitive inhibitor of FAK with IC50 of 4 nM in a cell-free assay, ~50- to 250-fold selective for FAK than Pyk2, CDK1/7 and GSK-3β. PF-573228 induces apoptosis.

PF-573228化学構造

CAS No. 869288-64-2

サイズ 価格(税別) 在庫状況
10mM (1mL in DMSO) JPY 28500 国内在庫あり
JPY 22000 国内在庫あり
JPY 85500 国内在庫あり
JPY 598500 国内在庫なし(納期7~10日)

代表番号: 045-509-1970|電子メール:[email protected]
よく尋ねられる質問

文献中Selleckの製品使用例(87)

製品安全説明書

現在のバッチを見る: 純度: 99.92%
99.92

PF-573228関連製品

シグナル伝達経路

FAK阻害剤の選択性比較

Cell Data

Cell Lines Assay Type Concentration Incubation Time 活性情報 PMID
FasR Kinase assay ~10 μM inhibits the phosphorylation of FAK Tyr397 with IC50 of 130 nM 20354780
TamR Kinase assay ~10 μM inhibits the phosphorylation of FAK Tyr397 with IC50 of 50 nM 20354780
MCF7 Kinase assay ~10 μM inhibits the phosphorylation of FAK Tyr397 with IC50 of 430 nM 20354780
platelet Function assay 1 μM blocks calcium mobilization and dense granule secretion 19716803
platelet Function assay 1 μM leads to inhibition of PAK and AKT 19716803
platelet Function assay 1 μM inhibits platelet aggregation and spreading 19716803
REF52 Function assay 10 μM blocks serum and FN-stimulated migration 17395594
REF52 Apoptosis assay 10 μM induces apoptosis 17395594
MDCK Apoptosis assay 10 μM induces apoptosis 17395594
REF52 Growth inhibitory assay 10 μM significantly inhibits cell growth. 17395594
PC3 Growth inhibitory assay 10 μM significantly inhibits cell growth. 17395594
MDCK Kinase assay ~10 μM inhibits the phosphorylation of FAK Tyr397 with IC50 of 500 nM 17395594
F-G Kinase assay ~10 μM inhibits the phosphorylation of FAK Tyr397 with IC50 of 30 nM 17395594
L3.6p1 Kinase assay ~10 μM inhibits the phosphorylation of FAK Tyr397 with IC50 of 300 nM 17395594
SKOV-3 Kinase assay ~10 μM inhibits the phosphorylation of FAK Tyr397 with IC50 of 50 nM 17395594
PC3 Kinase assay ~10 μM inhibits the phosphorylation of FAK Tyr397 with IC50 of 100 nM 17395594
REF52 Kinase assay ~10 μM inhibits the phosphorylation of FAK Tyr397 with IC50 of ~100 nM 17395594
A431 Kinase assay ~10 μM inhibits FAK phosphorylation with IC50 of 11 nM 17395594
TamR Function assay 1 μM inhibits cell migration 20354780
FasR Function assay 1 μM inhibits cell migration 20354780
endothelial cell Kinase assay 40 nM inhibits H2O2-induced phosphorylation of FAK 21212402
endothelial cell Function assay 40 nM inhibits H2O2-induced stress fiber formation 21212402
endothelial cell Apoptosis assay 40 nM inhibits apoptosis 21212402
GH3 Function assay 3 μM increases IK(Ca) amplitude 21925512
GH3 Function assay 3 μM enhances BKCa-channel activity 21925512
HUVEC cytotoxicity assay ~10 μM impairs endothelial cell viability 22075057
HUVEC Kinase assay 5 μM inhibits FAK kinase activity 22075057
HUVEC Function assay 5 μM induces cell cycle arrest 22075057
HUVEC Apoptosis assay 5 μM induces apoptosis 22075057
HUVEC Function assay 5 μM impedes endothelial cell migration and alters the cellular actin cytoskeleton 22075057
HUVEC Function assay 5 μM blocks HUVEC sprouting on collagen I gels 22075057
human peripheral blood T cells Kinase assay ~10 μM inhibits site-specific phosphorylation of FAK 23928188
human peripheral blood T cells Function assay ~10 μM impairs TCR-induced T cell morphological changes and alters activity of RhoA 23928188
human peripheral blood T cells Function assay ~10 μM inhibits phosphorylation of ZAP-70 and LAT 23928188
human peripheral blood T cells Function assay ~10 μM impairs Antigen-dependent T cell conjugation 23928188
4T1 Function assay abolishes the interaction between β3 integrin and TβR-II 19740433
U-2 OS qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells 29435139
A673 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells 29435139
Saos-2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells 29435139
BT-37 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells 29435139
RD qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells 29435139
SK-N-SH qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells 29435139
MG 63 (6-TG R) qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells 29435139
NB1643 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells 29435139
OHS-50 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells 29435139
SJ-GBM2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells 29435139
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells 29435139
NB-EBc1 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells 29435139
LAN-5 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells 29435139
他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

生物活性

製品説明 PF-573228 is an ATP-competitive inhibitor of FAK with IC50 of 4 nM in a cell-free assay, ~50- to 250-fold selective for FAK than Pyk2, CDK1/7 and GSK-3β. PF-573228 induces apoptosis.
Targets
FAK [1]
(Cell-free assay)
4 nM
In Vitro
In vitro PF 573228 blocks the phosphorylation of FAK Tyr397 in REF52 cells, PC3 cells, SKOV-3 cells, L3.6p1 and F-G, MDCK cells with IC50 of 30-500 nM. However, PF 573228 (1 μM) with 80% inhibition of FAK phosphorylation fails to inhibit cell growth or apoptosis. Similar treatment of cells with PF-228 resulted in inhibition of serum or FN-directed migration and decreased focal adhesion turnover. [1]
Kinase Assay Affinity determination
Purified activated FAK kinase domain (amino acids 410–689) is reacted with 50 μM ATP, and 10 μg/well of a random peptide polymer of Glu and Tyr (molar ratio of 4:1), poly(Glu/Tyr) in kinase buffer (50 mM HEPES, pH 7.5, 125 mM NaCl, 48 mM MgCl2) for 15 min. Phosphorylation of poly(Glu/Tyr) is challenged with serially diluted compounds at 1/2-Log concentrations starting at a top concentration of 1 μM. Each concentration is run in triplicate. Phosphorylation of poly(Glu/Tyr) is detected with a general anti-phospho-tyrosine (PY20) antibody, followed by horseradish peroxidase-conjugated goat anti-mouse IgG antibody. The standard horseradish peroxidase substrate 3, 3
細胞実験 細胞株 REF52 or PC3 cells
濃度 ~10 μM
反応時間 3 days
実験の流れ

Growth assays are performed by seeding 1 × 104 REF52 or PC3 cells/well of a 24-well plate in triplicate 24 h prior to daily treatment with the indicated concentrations of each inhibitor for 3 days. Subsequently, the cells are harvested and counted.

実験結果図 Methods Biomarkers 結果図 PMID
Western blot cyclin B1 p-FAK / FAK Lamin A / Lamin C 30761269
Immunofluorescence FAK / F-actin Emerin 30761269
Growth inhibition assay Cell viability 30761269
In Vivo
In Vivo Inhibition of FAK by PF-573,228 in Ctrl-MT mice leads to a significant suppression of mammary tumorigenesis as well as lung metastasis. In contrast, treatment of MFCKO-MT mice with PF-573,228 did not affect the initiation of mammary tumors in these mice, as would be expected due to the absence of FAK in mammary epithelial cells of these mice [2].
動物実験 動物モデル Ctrl-MT and MFCKO-MT mice
投与量 5 mg/kg
投与経路 oral administration

化学情報

分子量 491.49 化学式

C22H20F3N5O3S

CAS No. 869288-64-2 SDF Download PF-573228 SDFをダウンロードする
Smiles CS(=O)(=O)C1=CC=CC(=C1)CNC2=NC(=NC=C2C(F)(F)F)NC3=CC4=C(C=C3)NC(=O)CC4
保管

In vitro
Batch:

DMSO : 26 mg/mL ( (52.9 mM); 吸湿したDMSOは溶解度を減少させます。新しいDMSOをご使用ください。)

Water : Insoluble

Ethanol : Insoluble

モル濃度計算器

in vivo
Batch:

Add solvents to the product individually and in order.

投与溶液組成計算機

実験計算

モル濃度計算器

質量 濃度 体積 分子量

投与溶液組成計算機(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)

mg/kg g μL

ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)

% DMSO % % Tween 80 % ddH2O
%DMSO %

計算結果:

投与溶媒濃度: mg/ml;

DMSOストック溶液調製方法: mg 試薬を μL DMSOに溶解する(濃度 mg/mL, 注:濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法:Take μL DMSOストック溶液に μL PEG300,を加え、完全溶解後μL Tween 80,を加えて完全溶解させた後 μL ddH2O,を加え完全に溶解させます。

投与溶媒調製方法:μL DMSOストック溶液に μL Corn oil,を加え、完全溶解。

注意:1.ストック溶液に沈殿、混濁などがないことをご確認ください;
2.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

大学・企業名を記入してください
名前を記入してください
電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
お問い合わせ内容をご入力ください

よくある質問(FAQ)

質問1:
Would you please let me know the detail of how to dissolve PF-573228 (Catalog No.S2013) for in vivo study (oral administration)?

回答
PF-573228 in 30% PEG400+0.5% Tween80+ 5% Propylene glycol at 30mg/ml is a suspension. If you will use the compound for oral gavage, this suspension is fine for it.

Tags: PF-573228を買う | PF-573228 ic50 | PF-573228供給者 | PF-573228を購入する | PF-573228費用 | PF-573228生産者 | オーダーPF-573228 | PF-573228化学構造 | PF-573228分子量 | PF-573228代理店